Lv72
3428 积分 2022-01-17 加入
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
8小时前
待确认
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
8小时前
已完结
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
25天前
已完结
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
2个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
2个月前
已完结
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
2个月前
已完结
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
2个月前
已完结
Degradation of the Estrogen Receptor in Breast Cancer
2个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
3个月前
已完结
Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
3个月前
已完结
皖公网安备34019202002308
